Technological offer

New compounds to treat parasitic diseases such as Chagas disease, leishmaniasis and trypanosomiasias. These derivatives act on a new target: G-cuadruplex DNA

Compounds useful as reversible visible-light-regulated antagonists for the localized and temporally restricted activation of beta-adrenoceptors, with application for the treatment of ocular diseases such as glaucoma.

New antiviral compound against HSV-1 and HSV-2 that can be used in combination with other drugs or to treat resistant strains to conventional antivirals.

Selective SGK1 kinase inhibitors, blood-brain barrier-permeable, as drug candidates for the treatment of neurodegenerative diseases (such as Parkinson’s or Alzheimer’s disease) or cardiovascular diseases (such as hypertension).

New family of compounds with demonstrated in vitro efficacy against intracellular parasites responsible for leishmaniasis and American trypanosomiasis or Chagas disease. Pharmacokinetic and toxicity studies have been conducted in rats, as well as preliminary efficacy studies in a murine model.

An in vitro screening method by NMR spectroscopy of potential therapeutic compounds for Congenital Central Hypoventilation Syndrome (CCHS). The method is based in the identification of active agents that inhibit secondary structure changes in PHOX2B transcription factor.

Novel glycolipid mimetics able to express anti-inflammatory or adjuvant activity in a context dependent manner. The compounds can be used for the treatment of immune diseases cursed with Th1/Th2 imbalance or as vaccine adjuvants.

New family of molecules derived from Isoquercetin for the treatment and/or prevention of inflammatory and degenerative eye diseases.

Compounds useful as reversible light-regulated agonists for activation of Vitamin D receptor (VDR) using wavelengths suitable for phototherapy, that would avoid the appearance of secondary effects, with application for the treatment of diseases that involve an alteration of the VDR function.

Design of a novel proteolytic set of chimeras (26STACs) directed at the degradation of the ceramide transfer protein CERT-1 by the proteasome, in an E3-independent manner, for its use in the treatment of breast cancer.